Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pelitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 14/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pelitinib SCHEMBL29623744 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL29385637 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL93756 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL29349785 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL93757 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL8132957 | 0.93 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL6382792 | 0.93 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL12641715 | 0.92 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL10108217 | 0.92 | EGFR (0.85) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL14944414 | 0.92 | EGFR (0.85) | EGFRERBB2STK25CITCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| US-12539304-B2 | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor | PFIZER INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4646414-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4646413-A1 | SOLID FORMS OF A CDK2 INHIBITOR | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4646416-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4013404-A1 | METHODS OF TREATING CANCER | F. Hoffmann-La Roche AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| CN-114514032-A | Angiotensin type 2 (AT2) receptor agonists for the treatment of cancer | 兰提欧派普有限公司 | 2022-05-17 | — | — | CN | disclosed |
| US-20220089596-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2022-03-24 | — | — | US | disclosed |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | PFIZER INC. (US) | 2022-03-24 | — | — | US | disclosed |
| CN-114222576-A | Methods of treating cancer | F·霍夫曼-罗氏股份公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-107794302-B | Method for determining responsiveness of cancer to epidermal growth factor receptor targeted therapy | 综合医院公司 | 2022-03-15 | — | — | CN | disclosed |
| US-11253515-B2 | Pharmaceutical compositions and dosage forms | IGNYTA, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| CN-113975393-A | Methods of treating gefitinib resistant cancers | 综合医院公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113952338-A | Methods of treating gefitinib resistant cancers | 综合医院公司 | 2022-01-21 | — | — | CN | disclosed |
| CN-113952459-A | Methods of treating gefitinib resistant cancers | 综合医院公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594275-B2 | Immunophilin binding agents and uses thereof | CCR1, CCRL2, CCR3 | EGFR 2717/4885ERBB2 1975/4885STK25 4881/4885 |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CTRB1, CTRB2, CPN1 | EGFR 2524/4885ERBB2 4273/4885STK25 3021/4885 |
| US-12539304-B2 | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor | CDK4, CDK2, CDK6 | EGFR 271/4885ERBB2 108/4885STK25 222/4885 |
| US-11253515-B2 | Pharmaceutical compositions and dosage forms | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | EGFR 1457/4885ERBB2 1221/4885STK25 3145/4885 |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | CCRL2, CFB, CCR3 | EGFR 1974/4885ERBB2 1701/4885STK25 4856/4885 |
| US-20220089580-A1 | CYCLIN DEPENDENT KINASE INHIBITORS | CCNY, CCNI, CCNK | EGFR 575/4885ERBB2 799/4885STK25 437/4885 |
| US-20220089596-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | PRCP, PREP, TMPRSS15 | EGFR 3431/4885ERBB2 4255/4885STK25 1774/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | EGFR 604/4885ERBB2 318/4885STK25 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.